Market Cap 1.60B
Revenue (ttm) 0.00
Net Income (ttm) -133.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 433,600
Avg Vol 859,416
Day's Range N/A - N/A
Shares Out 105.35M
Stochastic %K 40%
Beta 0.28
Analysts Strong Sell
Price Target $37.69

Company Profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe...

Industry: Biotechnology
Sector: Healthcare
Phone: 720 262 7002
Address:
1715 38th Street, Boulder, United States
S_Franconi
S_Franconi Oct. 15 at 5:40 PM
$EWTX Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet https://stocktwits.com/news-articles///undefined/chDcUgnbbcyw4
0 · Reply
The_Real_Heisenberg
The_Real_Heisenberg Oct. 9 at 1:39 PM
$ATOS We got a runner... $XBI $VKTX $EWTX
3 · Reply
The_Real_Heisenberg
The_Real_Heisenberg Oct. 8 at 4:34 PM
$ATOS $XBI $EWTX $VKTX Anyone up for a Golden Cross trade? Get in now, were gonna go much much higher. Its just begun.
0 · Reply
Quantumup
Quantumup Oct. 6 at 1:49 PM
Barclays⬆️the PT on $CYTK to $82 from $71 and reiterated at an Overweight rating. $BMY $EWTX Barclays said in its note: Ahead of aficamten Ph3 ACACIA data (1H26, likely March/April) in non-obstructive hypertrophic cardiomyopathy (nHCM), we spoke with 2 KOLs and conducted a deep dive on historical clinical data and statistical analysis. We see a high prob for a positive outcome for dual primary endpoints KCCQ-CSS (>75%) and pVO2 (>55%). We expect aficamten to become the first approved drug in nHCM and continue to see a high probability of on time (PDUFA Dec 26) approval in oHCM with a differentiated label. Based on our KOL feedback, we believe aficamten with superior safety profile (therefore operational ease of use) would become the preferred therapy in oHCM/nHCM. Reiterate OW and increase our PT to $82.
0 · Reply
S_Franconi
S_Franconi Oct. 2 at 2:26 PM
$EWTX Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society https://investors.edgewisetx.com/news/default.aspx
0 · Reply
Quantumup
Quantumup Oct. 1 at 12:12 PM
Stifel trimmed the PT on $CYTK to $95 from $96 and maintained at a Buy rating to Reflect the Company's Recently Upsized Convertible Notes Offering. $BMY $EWTX This is what Stifel had to say in its note to investors: Following the recent late-cycle meeting, CYTK continues to expect a differentiated REMS/label where, along with recent strong MAPLE data, management expects aficamten to (1) expand the CMI prescriber base; and (2) obtain preferential share vs. Camzyos -- potentially even within the first year. Meanwhile, in-light of ODYSSEY (almost working, despite dosing challenges) management's confident in ACACIA-HCM, highlighting recent FOREST data (consistent efficacy; patients dosed to -- and safely maintained at -- aficamten's highest doses) and their expertise in executing HCM trials. We are also updating our model to reflect their recent convert deal -- that, along with routine model maintenance, brings our TP to $95 (vs. $96).
0 · Reply
Quantumup
Quantumup Sep. 30 at 12:41 PM
H.C. Wainwright y'day reiterated $CYTK Buy/$120 $BMY $EWTX $AZN $PFE HCW said: At the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025, Cytokinetics presented additional exercise performance data from the Phase 3 MAPLE-HCM trial evaluating aficamten vs. metoprolol in oHCM patients. HCW additionally said:
0 · Reply
Quantumup
Quantumup Sep. 29 at 11:46 AM
Stifel reiterated Favorite Idea $CYTK at Buy/$96 $BMY $EWTX Stifel said in its note:
0 · Reply
chrsc
chrsc Sep. 24 at 3:41 PM
$EWTX breaking out
0 · Reply
PatriciaStemple542
PatriciaStemple542 Sep. 21 at 12:31 PM
$EWTX Biotech with clinical catalyst. High risk speculation. Trading near cash value. No pattern.
1 · Reply
Latest News on EWTX
Analysts Think There's Still Time To Get In On Edgewise

Sep 30, 2024, 12:12 PM EDT - 1 year ago

Analysts Think There's Still Time To Get In On Edgewise


Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

Sep 25, 2024, 11:50 AM EDT - 1 year ago

Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge


S_Franconi
S_Franconi Oct. 15 at 5:40 PM
$EWTX Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet https://stocktwits.com/news-articles///undefined/chDcUgnbbcyw4
0 · Reply
The_Real_Heisenberg
The_Real_Heisenberg Oct. 9 at 1:39 PM
$ATOS We got a runner... $XBI $VKTX $EWTX
3 · Reply
The_Real_Heisenberg
The_Real_Heisenberg Oct. 8 at 4:34 PM
$ATOS $XBI $EWTX $VKTX Anyone up for a Golden Cross trade? Get in now, were gonna go much much higher. Its just begun.
0 · Reply
Quantumup
Quantumup Oct. 6 at 1:49 PM
Barclays⬆️the PT on $CYTK to $82 from $71 and reiterated at an Overweight rating. $BMY $EWTX Barclays said in its note: Ahead of aficamten Ph3 ACACIA data (1H26, likely March/April) in non-obstructive hypertrophic cardiomyopathy (nHCM), we spoke with 2 KOLs and conducted a deep dive on historical clinical data and statistical analysis. We see a high prob for a positive outcome for dual primary endpoints KCCQ-CSS (>75%) and pVO2 (>55%). We expect aficamten to become the first approved drug in nHCM and continue to see a high probability of on time (PDUFA Dec 26) approval in oHCM with a differentiated label. Based on our KOL feedback, we believe aficamten with superior safety profile (therefore operational ease of use) would become the preferred therapy in oHCM/nHCM. Reiterate OW and increase our PT to $82.
0 · Reply
S_Franconi
S_Franconi Oct. 2 at 2:26 PM
$EWTX Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society https://investors.edgewisetx.com/news/default.aspx
0 · Reply
Quantumup
Quantumup Oct. 1 at 12:12 PM
Stifel trimmed the PT on $CYTK to $95 from $96 and maintained at a Buy rating to Reflect the Company's Recently Upsized Convertible Notes Offering. $BMY $EWTX This is what Stifel had to say in its note to investors: Following the recent late-cycle meeting, CYTK continues to expect a differentiated REMS/label where, along with recent strong MAPLE data, management expects aficamten to (1) expand the CMI prescriber base; and (2) obtain preferential share vs. Camzyos -- potentially even within the first year. Meanwhile, in-light of ODYSSEY (almost working, despite dosing challenges) management's confident in ACACIA-HCM, highlighting recent FOREST data (consistent efficacy; patients dosed to -- and safely maintained at -- aficamten's highest doses) and their expertise in executing HCM trials. We are also updating our model to reflect their recent convert deal -- that, along with routine model maintenance, brings our TP to $95 (vs. $96).
0 · Reply
Quantumup
Quantumup Sep. 30 at 12:41 PM
H.C. Wainwright y'day reiterated $CYTK Buy/$120 $BMY $EWTX $AZN $PFE HCW said: At the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025, Cytokinetics presented additional exercise performance data from the Phase 3 MAPLE-HCM trial evaluating aficamten vs. metoprolol in oHCM patients. HCW additionally said:
0 · Reply
Quantumup
Quantumup Sep. 29 at 11:46 AM
Stifel reiterated Favorite Idea $CYTK at Buy/$96 $BMY $EWTX Stifel said in its note:
0 · Reply
chrsc
chrsc Sep. 24 at 3:41 PM
$EWTX breaking out
0 · Reply
PatriciaStemple542
PatriciaStemple542 Sep. 21 at 12:31 PM
$EWTX Biotech with clinical catalyst. High risk speculation. Trading near cash value. No pattern.
1 · Reply
Quantumup
Quantumup Sep. 17 at 11:43 AM
Goldman Sachs initiated coverage of $TRDA at an Early-Stage Biotech rating. [ $SRPT $EWTX $PTCT SLDB $RGNX PEPG RNA] Goldman Sachs said: We initiate coverage of Entrada Therapeutics ( $TRDA) with an Early-Stage Biotech (ESB) designation. In our view, $TRDA's proprietary Endosomal Escape Vehicle (EEV) platform is differentiated from other delivery peptide approaches, and as such, we see best-in-class potential driven by key properties including: 1) enhanced cellular uptake, 2) a wider therapeutic index, and most notably 3) a better safety profile. Within the broader Duchenne muscular dystrophy (DMD) treatment paradigm, we continue to evaluate the positioning of gene therapies relative to exon-skipping therapeutics following recent safety events observed with $SRPT's Elevidys. With the barriers to entry for next generation DMD therapeutics lowered, we are cautiously positive on the efficacy/safety profile of $TRDA's burgeoning clinical-stage portfolio and translation of data into the clinic.
1 · Reply
Trainguy1
Trainguy1 Sep. 16 at 1:15 PM
$EWTX FYI - The person who brought the share price down to $12.49 just a few minutes ago did it by selling 1 share.
0 · Reply
JarvisFlow
JarvisFlow Sep. 10 at 10:00 AM
JP Morgan has adjusted their stance on Edgewise Therapeutics ( $EWTX ), setting the rating to Overweight with a target price of 45 → 40.
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 7:57 AM
$EWTX Outstanding article that hits the mark on EWTX's current state. So if you want to refresh your EWTX insights or learn about EWTX from scratch, this is a must read. https://beyondspx.com/quote/EWTX/analysis/edgewise-therapeutics-unlocking-muscle-potential-with-precision-small-molecules-nasdaq-ewtx
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 4 at 10:14 AM
WATCHLIST SEP 04 2025 $IDYA Ideaya Biosciences Enrolls First Patient In Phase 1/2 Trial Of IDE397, A Potential First-In-Class MAT2A Inhibitor, And Trodelvy In MTAP-Deletion Non-Small Cell Lung Cancer $DOW Dow Launches DOWSIL™ EG-4175 Silicone Gel to Enable Higher Voltage Power Electronics in Electric Vehicles and Renewable Energy Technologies $SNY Sanofi's Amlitelimab Reinforces Potential As First And Only Atopic Dermatitis Treatment With Possible Dosing Only Four Times Per Year $EWTX Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules $PRM Perimeter Solutions and USDA Enter Historic Five-Year Agreement, Strengthening Wildfire Response and Expanding Value-Added Services
0 · Reply
S_Franconi
S_Franconi Sep. 3 at 11:35 PM
$EWTX Edgewise Therapeutics, Inc. (EWTX Quick QuoteEWTX - Free Report) closed the last trading session at $14.35, gaining 5.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $39.17 indicates a 173% upside potential. https://www.zacks.com/stock/news/2746009/wall-street-analysts-believe-edgewise-therapeutics-ewtx-could-rally-17296-heres-is-how-to-trade?cid=CS-STOCKTWITS-HL-tale_of_the_tape|consensus_price_target-2746009&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_551_2746009
1 · Reply
chrsc
chrsc Sep. 2 at 5:37 PM
$EWTX encouraging strength on a very red day.
0 · Reply
Quantumup
Quantumup Sep. 2 at 1:53 PM
Truist reiterated $CYTK Buy-$70 and said, Ph3 MAPLE data makes strong case for 1L oHCM aficamten use, gives afi an edge, in our view $BMY $EWTX $NVS $AZN CRMD Truist added, We remain buyers of $CYTK shares following Ph3 MAPLE-HCM data at ESC this past weekend which in our view support 1L and potentially best-in-class CMI profile for aficamten. We believe that the stock is currently undervalued and see potential for 20-30% upside in the near-term and >75% upside from CMP over next 6-12 months around approval (PDUFA 12/26) and launch. While we believe it could take some time to supplant beta blockers in 1L, Ph3 MAPLE data showing aficamten's stat-sig improvement vs. metoprolol make the case for 1L use for aficamten and see these data as a differentiator vs mavacamten. Reiterate Buy.
0 · Reply
YoloAlfred
YoloAlfred Aug. 29 at 8:59 PM
$SRPT $EWTX $CPIX 😜Have a great weekend (mouse MODEL)
0 · Reply
haha1978
haha1978 Aug. 29 at 7:41 PM
$SRPT $EWTX $CPIX keep cpix on your watch list. DMD P2 OLE 3 year study is due weeks away for cardiomyopathy and if ifetroban is good should pop it over $10.00. They have a 41 sample size on high dose ifetroban. Mouse models were stellar.
0 · Reply
BioResearcher
BioResearcher Aug. 29 at 7:37 PM
0 · Reply
Trainguy1
Trainguy1 Aug. 27 at 1:03 PM
$EWTX The Wall Street analysts that put out 1-year share price forecasts this month predicted from $30 to $50 per share. Notice that all analysts except one are rated 4 to 5 stars.
0 · Reply